ArticleEndocrine, metabolic & immune disorders drug targets2026
Acromegaly and Morris Syndrome: Description of a Clinical Case
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcromegaly associated with Morris syndrome has never been reported in the literature. CASE PRESENTATION: We present the case of a 49-year-old woman with Morris syndrome, diagnosed in 1992, who has undergone gonadectomy and hormone replacement therapy for about 15 years. The patient was referred to our centre for the clinical suspicion of acromegaly in June 2022, for the enlargement of the acral extremities and the development of prognathism in the last 10 years. The patient underwent mandibular reduction surgery and removal of a tubular adenoma of the colon in 2010. In June 2021, the patient performed random GH, IGF-I, and prolactin (PRL) dosages that confirmed the diagnosis of acromegaly. A contrasted pituitary MRI showed the presence of an 8 mm intrasellar pituitary adenoma. Therefore, a transsphenoidal resection of the pituitary tumor was conducted in September 2021. The histological examination proved the diagnosis of somatotropinoma. At the last follow-up at our center in June 2024, the patient presented in a fair general clinical condition, with recovery of related acromegaly symptoms, normalized IGF-I levels, and a negative pituitary MRI for signs of somatotropinoma recurrence.
conclusionOur clinical case describes for the first time the association between Morris syndrome and acromegaly. Due to the singularity of this case, we decided to conduct more in-depth genetic analyses through a clinical exome study and CGH Array evaluation, which, however, did not lead to the discovery of a genetic association between the two conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.